Skip to main content
Top
Published in: BMC Infectious Diseases 1/2013

Open Access 01-12-2013 | Research article

Effect of metallo-β-lactamase production and multidrug resistance on clinical outcomes in patients with Pseudomonas aeruginosabloodstream infection: a retrospective cohort study

Authors: Matthias Willmann, Ines Kuebart, Matthias Marschal, Klaus Schröppel, Wichard Vogel, Ingo Flesch, Uwe Markert, Ingo B Autenrieth, Florian Hölzl, Silke Peter

Published in: BMC Infectious Diseases | Issue 1/2013

Login to get access

Abstract

Background

Blood stream infections (BSI) with Pseudomonas aeruginosa lead to poor clinical outcomes. The worldwide emergence and spread of metallo-β-lactamase (MBL) producing, often multidrug-resistant organisms may further aggravate this problem. Our study aimed to investigate the effect of MBL-producing P. aeruginosa (MBL-PA) and various other resistance phenotypes on clinical outcomes.

Methods

A retrospective cohort study was conducted in three German hospitals. Medical files from 2006 until 2012 were studied, and a number of 113 patients with P. aeruginosa BSI were included. The presence of VIM, IMP and NDM genes was detected using molecular techniques. Genetic relatedness was assessed through multilocus sequence typing (MLST). The effect of resistance patterns or MBL production on clinical outcomes was investigated by using multivariate Cox regression models.

Results

In-hospital mortality was significantly higher in patients with MBL-PA and multidrug-resistant P. aeruginosa. However, neither BSI with MBL-PA nor BSI with various resistance phenotypes of P. aeruginosa were independently associated with mortality or length of hospital stay. In multivariate models, the SAPS II score (HR 1.046), appropriate definitive treatment (HR range 0.25-0.26), and cardiovascular disease (HR range 0.44-0.46) were independent predictors of mortality. Concomitant infections were associated with an excess length of stay (HR < 1).

Conclusions

Medication with appropriate antimicrobial agents at any time during the course of infection remains the key for improving clinical outcomes in patients with P. aeruginosa BSI and should be combined with a strict implementation of routine infection control measures.
Literature
1.
go back to reference Gould IM, Wise R: Pseudomonas aeruginosa: clinical manifestations and management. Lancet. 1985, 2 (8466): 1224-1227.CrossRefPubMed Gould IM, Wise R: Pseudomonas aeruginosa: clinical manifestations and management. Lancet. 1985, 2 (8466): 1224-1227.CrossRefPubMed
2.
go back to reference Kang CI, Kim SH, Kim HB, Park SW, Choe YJ, Oh MD, Kim EC, Choe KW: Pseudomonas aeruginosa bacteremia: risk factors for mortality and influence of delayed receipt of effective antimicrobial therapy on clinical outcome. Clin Infect Dis. 2003, 37 (6): 745-751. 10.1086/377200.CrossRefPubMed Kang CI, Kim SH, Kim HB, Park SW, Choe YJ, Oh MD, Kim EC, Choe KW: Pseudomonas aeruginosa bacteremia: risk factors for mortality and influence of delayed receipt of effective antimicrobial therapy on clinical outcome. Clin Infect Dis. 2003, 37 (6): 745-751. 10.1086/377200.CrossRefPubMed
3.
go back to reference Tumbarello M, Repetto E, Trecarichi EM, Bernardini C, De Pascale G, Parisini A, Rossi M, Molinari MP, Spanu T, Viscoli C, et al: Multidrug-resistant Pseudomonas aeruginosa bloodstream infections: risk factors and mortality. Epidemiol Infect. 2011, 139 (11): 1740-1749. 10.1017/S0950268810003055.CrossRefPubMed Tumbarello M, Repetto E, Trecarichi EM, Bernardini C, De Pascale G, Parisini A, Rossi M, Molinari MP, Spanu T, Viscoli C, et al: Multidrug-resistant Pseudomonas aeruginosa bloodstream infections: risk factors and mortality. Epidemiol Infect. 2011, 139 (11): 1740-1749. 10.1017/S0950268810003055.CrossRefPubMed
4.
go back to reference Goel N, Wattal C, Oberoi JK, Raveendran R, Datta S, Prasad KJ: Trend analysis of antimicrobial consumption and development of resistance in non-fermenters in a tertiary care hospital in Delhi, India. J Antimicrob Chemother. 2011, 66 (7): 1625-1630. 10.1093/jac/dkr167.CrossRefPubMed Goel N, Wattal C, Oberoi JK, Raveendran R, Datta S, Prasad KJ: Trend analysis of antimicrobial consumption and development of resistance in non-fermenters in a tertiary care hospital in Delhi, India. J Antimicrob Chemother. 2011, 66 (7): 1625-1630. 10.1093/jac/dkr167.CrossRefPubMed
5.
go back to reference Croughs PD, Li B, Hoogkamp-Korstanje JA, Stobberingh E: Thirteen years of antibiotic susceptibility surveillance of Pseudomonas aeruginosa from intensive care units and urology services in the Netherlands. Eur J Clin Microbiol Infect Dis. 2013, 32 (2): 283-288. 10.1007/s10096-012-1741-4.CrossRefPubMed Croughs PD, Li B, Hoogkamp-Korstanje JA, Stobberingh E: Thirteen years of antibiotic susceptibility surveillance of Pseudomonas aeruginosa from intensive care units and urology services in the Netherlands. Eur J Clin Microbiol Infect Dis. 2013, 32 (2): 283-288. 10.1007/s10096-012-1741-4.CrossRefPubMed
6.
go back to reference Lautenbach E, Synnestvedt M, Weiner MG, Bilker WB, Vo L, Schein J, Kim M: Imipenem resistance in Pseudomonas aeruginosa: emergence, epidemiology, and impact on clinical and economic outcomes. Infect Control Hosp Epidemiol. 2010, 31 (1): 47-53. 10.1086/649021.CrossRefPubMed Lautenbach E, Synnestvedt M, Weiner MG, Bilker WB, Vo L, Schein J, Kim M: Imipenem resistance in Pseudomonas aeruginosa: emergence, epidemiology, and impact on clinical and economic outcomes. Infect Control Hosp Epidemiol. 2010, 31 (1): 47-53. 10.1086/649021.CrossRefPubMed
7.
go back to reference Willmann M, Marschal M, Holzl F, Schroppel K, Autenrieth IB, Peter S: Time series analysis as a tool to predict the impact of antimicrobial restriction in antibiotic stewardship programs using the example of multidrug-resistant Pseudomonas aeruginosa. Antimicrob Agents Chemother. 2013, 57 (4): 1797-1803. 10.1128/AAC.02142-12.CrossRefPubMedPubMedCentral Willmann M, Marschal M, Holzl F, Schroppel K, Autenrieth IB, Peter S: Time series analysis as a tool to predict the impact of antimicrobial restriction in antibiotic stewardship programs using the example of multidrug-resistant Pseudomonas aeruginosa. Antimicrob Agents Chemother. 2013, 57 (4): 1797-1803. 10.1128/AAC.02142-12.CrossRefPubMedPubMedCentral
8.
go back to reference Valenza G, Joseph B, Elias J, Claus H, Oesterlein A, Engelhardt K, Turnwald D, Frosch M, Abele-Horn M, Schoen C: First survey of metallo-beta-lactamases in clinical isolates of Pseudomonas aeruginosa in a German university hospital. Antimicrob Agents Chemother. 2010, 54 (8): 3493-3497. 10.1128/AAC.00080-10.CrossRefPubMedPubMedCentral Valenza G, Joseph B, Elias J, Claus H, Oesterlein A, Engelhardt K, Turnwald D, Frosch M, Abele-Horn M, Schoen C: First survey of metallo-beta-lactamases in clinical isolates of Pseudomonas aeruginosa in a German university hospital. Antimicrob Agents Chemother. 2010, 54 (8): 3493-3497. 10.1128/AAC.00080-10.CrossRefPubMedPubMedCentral
9.
go back to reference Cornaglia G, Giamarellou H, Rossolini GM: Metallo-beta-lactamases: a last frontier for beta-lactams?. Lancet Infect Dis. 2011, 11 (5): 381-393. 10.1016/S1473-3099(11)70056-1.CrossRefPubMed Cornaglia G, Giamarellou H, Rossolini GM: Metallo-beta-lactamases: a last frontier for beta-lactams?. Lancet Infect Dis. 2011, 11 (5): 381-393. 10.1016/S1473-3099(11)70056-1.CrossRefPubMed
10.
go back to reference Riccio ML, Pallecchi L, Fontana R, Rossolini GM: In70 of plasmid pAX22, a bla(VIM-1)-containing integron carrying a new aminoglycoside phosphotransferase gene cassette. Antimicrob Agents Chemother. 2001, 45 (4): 1249-1253. 10.1128/AAC.45.4.1249-1253.2001.CrossRefPubMedPubMedCentral Riccio ML, Pallecchi L, Fontana R, Rossolini GM: In70 of plasmid pAX22, a bla(VIM-1)-containing integron carrying a new aminoglycoside phosphotransferase gene cassette. Antimicrob Agents Chemother. 2001, 45 (4): 1249-1253. 10.1128/AAC.45.4.1249-1253.2001.CrossRefPubMedPubMedCentral
11.
go back to reference Scoulica EV, Neonakis IK, Gikas AI, Tselentis YJ: Spread of bla(VIM-1)-producing E. coli in a university hospital in Greece: genetic analysis of the integron carrying the bla(VIM-1) metallo-beta-lactamase gene. Diagn Microbiol Infect Dis. 2004, 48 (3): 167-172. 10.1016/j.diagmicrobio.2003.09.012.CrossRefPubMed Scoulica EV, Neonakis IK, Gikas AI, Tselentis YJ: Spread of bla(VIM-1)-producing E. coli in a university hospital in Greece: genetic analysis of the integron carrying the bla(VIM-1) metallo-beta-lactamase gene. Diagn Microbiol Infect Dis. 2004, 48 (3): 167-172. 10.1016/j.diagmicrobio.2003.09.012.CrossRefPubMed
12.
go back to reference Bush K: New beta-lactamases in gram-negative bacteria: diversity and impact on the selection of antimicrobial therapy. Clin Infect Dis. 2001, 32 (7): 1085-1089. 10.1086/319610.CrossRefPubMed Bush K: New beta-lactamases in gram-negative bacteria: diversity and impact on the selection of antimicrobial therapy. Clin Infect Dis. 2001, 32 (7): 1085-1089. 10.1086/319610.CrossRefPubMed
13.
go back to reference Giske CG, Libisch B, Colinon C, Scoulica E, Pagani L, Fuzi M, Kronvall G, Rossolini GM: Establishing clonal relationships between VIM-1-like metallo-beta-lactamase-producing Pseudomonas aeruginosa strains from four European countries by multilocus sequence typing. J Clin Microbiol. 2006, 44 (12): 4309-4315. 10.1128/JCM.00817-06.CrossRefPubMedPubMedCentral Giske CG, Libisch B, Colinon C, Scoulica E, Pagani L, Fuzi M, Kronvall G, Rossolini GM: Establishing clonal relationships between VIM-1-like metallo-beta-lactamase-producing Pseudomonas aeruginosa strains from four European countries by multilocus sequence typing. J Clin Microbiol. 2006, 44 (12): 4309-4315. 10.1128/JCM.00817-06.CrossRefPubMedPubMedCentral
14.
go back to reference Hirakata Y, Yamaguchi T, Nakano M, Izumikawa K, Mine M, Aoki S, Kondoh A, Matsuda J, Hirayama M, Yanagihara K, et al: Clinical and bacteriological characteristics of IMP-type metallo-beta-lactamase-producing Pseudomonas aeruginosa. Clin Infect Dis. 2003, 37 (1): 26-32. 10.1086/375594.CrossRefPubMed Hirakata Y, Yamaguchi T, Nakano M, Izumikawa K, Mine M, Aoki S, Kondoh A, Matsuda J, Hirayama M, Yanagihara K, et al: Clinical and bacteriological characteristics of IMP-type metallo-beta-lactamase-producing Pseudomonas aeruginosa. Clin Infect Dis. 2003, 37 (1): 26-32. 10.1086/375594.CrossRefPubMed
15.
go back to reference Laupland KB, Parkins MD, Church DL, Gregson DB, Louie TJ, Conly JM, Elsayed S, Pitout JD: Population-based epidemiological study of infections caused by carbapenem-resistant Pseudomonas aeruginosa in the Calgary health region: importance of metallo-beta-lactamase (MBL)-producing strains. J Infect Dis. 2005, 192 (9): 1606-1612. 10.1086/444469.CrossRefPubMed Laupland KB, Parkins MD, Church DL, Gregson DB, Louie TJ, Conly JM, Elsayed S, Pitout JD: Population-based epidemiological study of infections caused by carbapenem-resistant Pseudomonas aeruginosa in the Calgary health region: importance of metallo-beta-lactamase (MBL)-producing strains. J Infect Dis. 2005, 192 (9): 1606-1612. 10.1086/444469.CrossRefPubMed
16.
go back to reference Zavascki AP, Barth AL, Goncalves AL, Moro AL, Fernandes JF, Martins AF, Ramos F, Goldani LZ: The influence of metallo-beta-lactamase production on mortality in nosocomial Pseudomonas aeruginosa infections. J Antimicrob Chemother. 2006, 58 (2): 387-392. 10.1093/jac/dkl239.CrossRefPubMed Zavascki AP, Barth AL, Goncalves AL, Moro AL, Fernandes JF, Martins AF, Ramos F, Goldani LZ: The influence of metallo-beta-lactamase production on mortality in nosocomial Pseudomonas aeruginosa infections. J Antimicrob Chemother. 2006, 58 (2): 387-392. 10.1093/jac/dkl239.CrossRefPubMed
17.
go back to reference Vandenbroucke JP, Von Elm E, Altman DG, Gotzsche PC, Mulrow CD, Pocock SJ, Poole C, Schlesselman JJ, Egger M: Strengthening the reporting of observational studies in epidemiology (STROBE): explanation and elaboration. PLoS Med. 2007, 4 (10): e297-10.1371/journal.pmed.0040297.CrossRefPubMedPubMedCentral Vandenbroucke JP, Von Elm E, Altman DG, Gotzsche PC, Mulrow CD, Pocock SJ, Poole C, Schlesselman JJ, Egger M: Strengthening the reporting of observational studies in epidemiology (STROBE): explanation and elaboration. PLoS Med. 2007, 4 (10): e297-10.1371/journal.pmed.0040297.CrossRefPubMedPubMedCentral
19.
go back to reference Calandra T, Cohen J: The international sepsis forum consensus conference on definitions of infection in the intensive care unit. Crit Care Med. 2005, 33 (7): 1538-1548. 10.1097/01.CCM.0000168253.91200.83.CrossRefPubMed Calandra T, Cohen J: The international sepsis forum consensus conference on definitions of infection in the intensive care unit. Crit Care Med. 2005, 33 (7): 1538-1548. 10.1097/01.CCM.0000168253.91200.83.CrossRefPubMed
20.
go back to reference Charlson ME, Pompei P, Ales KL, MacKenzie CR: A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987, 40 (5): 373-383. 10.1016/0021-9681(87)90171-8.CrossRefPubMed Charlson ME, Pompei P, Ales KL, MacKenzie CR: A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987, 40 (5): 373-383. 10.1016/0021-9681(87)90171-8.CrossRefPubMed
21.
go back to reference Le Gall JR, Lemeshow S, Saulnier F: A new simplified acute physiology score (SAPS II) based on a European/North American multicenter study. JAMA. 1993, 270 (24): 2957-2963. 10.1001/jama.1993.03510240069035.CrossRefPubMed Le Gall JR, Lemeshow S, Saulnier F: A new simplified acute physiology score (SAPS II) based on a European/North American multicenter study. JAMA. 1993, 270 (24): 2957-2963. 10.1001/jama.1993.03510240069035.CrossRefPubMed
23.
go back to reference Leclercq R, Canton R, Brown DF, Giske CG, Heisig P, Macgowan AP, Mouton JW, Nordmann P, Rodloff AC, Rossolini GM, et al: EUCAST expert rules in antimicrobial susceptibility testing. Clin Microbiol Infect. 2011, 19 (2): 141-160.CrossRefPubMed Leclercq R, Canton R, Brown DF, Giske CG, Heisig P, Macgowan AP, Mouton JW, Nordmann P, Rodloff AC, Rossolini GM, et al: EUCAST expert rules in antimicrobial susceptibility testing. Clin Microbiol Infect. 2011, 19 (2): 141-160.CrossRefPubMed
25.
go back to reference CLSI: Performance standards for antimicobial susceptibility testing. 2012, Wayne, PA: Clinical and Laboratory Standards Institute, 32 CLSI: Performance standards for antimicobial susceptibility testing. 2012, Wayne, PA: Clinical and Laboratory Standards Institute, 32
26.
go back to reference Pitout JD, Gregson DB, Poirel L, McClure JA, Le P, Church DL: Detection of Pseudomonas aeruginosa producing metallo-beta-lactamases in a large centralized laboratory. J Clin Microbiol. 2005, 43 (7): 3129-3135. 10.1128/JCM.43.7.3129-3135.2005.CrossRefPubMedPubMedCentral Pitout JD, Gregson DB, Poirel L, McClure JA, Le P, Church DL: Detection of Pseudomonas aeruginosa producing metallo-beta-lactamases in a large centralized laboratory. J Clin Microbiol. 2005, 43 (7): 3129-3135. 10.1128/JCM.43.7.3129-3135.2005.CrossRefPubMedPubMedCentral
27.
go back to reference Lee MF, Peng CF, Hsu HJ, Chen YH: Molecular characterisation of the metallo-beta-lactamase genes in imipenem-resistant Gram-negative bacteria from a university hospital in southern Taiwan. Int J Antimicrob Agents. 2008, 32 (6): 475-480. 10.1016/j.ijantimicag.2008.07.009.CrossRefPubMed Lee MF, Peng CF, Hsu HJ, Chen YH: Molecular characterisation of the metallo-beta-lactamase genes in imipenem-resistant Gram-negative bacteria from a university hospital in southern Taiwan. Int J Antimicrob Agents. 2008, 32 (6): 475-480. 10.1016/j.ijantimicag.2008.07.009.CrossRefPubMed
28.
go back to reference Lambert ML, Suetens C, Savey A, Palomar M, Hiesmayr M, Morales I, Agodi A, Frank U, Mertens K, Schumacher M, et al: Clinical outcomes of health-care-associated infections and antimicrobial resistance in patients admitted to European intensive-care units: a cohort study. Lancet Infect Dis. 2011, 11 (1): 30-38. 10.1016/S1473-3099(10)70258-9.CrossRefPubMed Lambert ML, Suetens C, Savey A, Palomar M, Hiesmayr M, Morales I, Agodi A, Frank U, Mertens K, Schumacher M, et al: Clinical outcomes of health-care-associated infections and antimicrobial resistance in patients admitted to European intensive-care units: a cohort study. Lancet Infect Dis. 2011, 11 (1): 30-38. 10.1016/S1473-3099(10)70258-9.CrossRefPubMed
29.
go back to reference Abbo A, Carmeli Y, Navon-Venezia S, Siegman-Igra Y, Schwaber MJ: Impact of multi-drug-resistant Acinetobacter baumannii on clinical outcomes. Eur J Clin Microbiol Infect Dis. 2007, 26 (11): 793-800. 10.1007/s10096-007-0371-8.CrossRefPubMed Abbo A, Carmeli Y, Navon-Venezia S, Siegman-Igra Y, Schwaber MJ: Impact of multi-drug-resistant Acinetobacter baumannii on clinical outcomes. Eur J Clin Microbiol Infect Dis. 2007, 26 (11): 793-800. 10.1007/s10096-007-0371-8.CrossRefPubMed
30.
go back to reference Durakovic N, Radojcic V, Boban A, Mrsic M, Sertic D, Serventi-Seiwerth R, Nemet D, Labar B: Efficacy and safety of colistin in the treatment of infections caused by multidrug-resistant Pseudomonas aeruginosa in patients with hematologic malignancy: a matched pair analysis. Intern Med. 2011, 50 (9): 1009-1013. 10.2169/internalmedicine.50.4270.CrossRefPubMed Durakovic N, Radojcic V, Boban A, Mrsic M, Sertic D, Serventi-Seiwerth R, Nemet D, Labar B: Efficacy and safety of colistin in the treatment of infections caused by multidrug-resistant Pseudomonas aeruginosa in patients with hematologic malignancy: a matched pair analysis. Intern Med. 2011, 50 (9): 1009-1013. 10.2169/internalmedicine.50.4270.CrossRefPubMed
31.
go back to reference Hachem RY, Chemaly RF, Ahmar CA, Jiang Y, Boktour MR, Rjaili GA, Bodey GP, Raad II: Colistin is effective in treatment of infections caused by multidrug-resistant Pseudomonas aeruginosa in cancer patients. Antimicrob Agents Chemother. 2007, 51 (6): 1905-1911. 10.1128/AAC.01015-06.CrossRefPubMedPubMedCentral Hachem RY, Chemaly RF, Ahmar CA, Jiang Y, Boktour MR, Rjaili GA, Bodey GP, Raad II: Colistin is effective in treatment of infections caused by multidrug-resistant Pseudomonas aeruginosa in cancer patients. Antimicrob Agents Chemother. 2007, 51 (6): 1905-1911. 10.1128/AAC.01015-06.CrossRefPubMedPubMedCentral
32.
go back to reference Montero M, Horcajada JP, Sorli L, Alvarez-Lerma F, Grau S, Riu M, Sala M, Knobel H: Effectiveness and safety of colistin for the treatment of multidrug-resistant Pseudomonas aeruginosa infections. Infection. 2009, 37 (5): 461-465. 10.1007/s15010-009-8342-x.CrossRefPubMed Montero M, Horcajada JP, Sorli L, Alvarez-Lerma F, Grau S, Riu M, Sala M, Knobel H: Effectiveness and safety of colistin for the treatment of multidrug-resistant Pseudomonas aeruginosa infections. Infection. 2009, 37 (5): 461-465. 10.1007/s15010-009-8342-x.CrossRefPubMed
33.
go back to reference Hirsch EB, Cottreau JM, Chang KT, Caeiro JP, Johnson ML, Tam VH: A model to predict mortality following Pseudomonas aeruginosa bacteremia. Diagn Microbiol Infect Dis. 2012, 72 (1): 97-102. 10.1016/j.diagmicrobio.2011.09.018.CrossRefPubMed Hirsch EB, Cottreau JM, Chang KT, Caeiro JP, Johnson ML, Tam VH: A model to predict mortality following Pseudomonas aeruginosa bacteremia. Diagn Microbiol Infect Dis. 2012, 72 (1): 97-102. 10.1016/j.diagmicrobio.2011.09.018.CrossRefPubMed
34.
go back to reference Aloush V, Navon-Venezia S, Seigman-Igra Y, Cabili S, Carmeli Y: Multidrug-resistant Pseudomonas aeruginosa: risk factors and clinical impact. Antimicrob Agents Chemother. 2006, 50 (1): 43-48. 10.1128/AAC.50.1.43-48.2006.CrossRefPubMedPubMedCentral Aloush V, Navon-Venezia S, Seigman-Igra Y, Cabili S, Carmeli Y: Multidrug-resistant Pseudomonas aeruginosa: risk factors and clinical impact. Antimicrob Agents Chemother. 2006, 50 (1): 43-48. 10.1128/AAC.50.1.43-48.2006.CrossRefPubMedPubMedCentral
35.
go back to reference Morata L, Cobos-Trigueros N, Martinez JA, Soriano A, Almela M, Marco F, Sterzik H, Nunez R, Hernandez C, Mensa J: Influence of multidrug resistance and appropriate empirical therapy on the 30-day mortality rate of Pseudomonas aeruginosa bacteremia. Antimicrob Agents Chemother. 2012, 56 (9): 4833-4837. 10.1128/AAC.00750-12.CrossRefPubMedPubMedCentral Morata L, Cobos-Trigueros N, Martinez JA, Soriano A, Almela M, Marco F, Sterzik H, Nunez R, Hernandez C, Mensa J: Influence of multidrug resistance and appropriate empirical therapy on the 30-day mortality rate of Pseudomonas aeruginosa bacteremia. Antimicrob Agents Chemother. 2012, 56 (9): 4833-4837. 10.1128/AAC.00750-12.CrossRefPubMedPubMedCentral
36.
go back to reference Lodise TP, Patel N, Kwa A, Graves J, Furuno JP, Graffunder E, Lomaestro B, McGregor JC: Predictors of 30-day mortality among patients with Pseudomonas aeruginosa bloodstream infections: impact of delayed appropriate antibiotic selection. Antimicrob Agents Chemother. 2007, 51 (10): 3510-3515. 10.1128/AAC.00338-07.CrossRefPubMedPubMedCentral Lodise TP, Patel N, Kwa A, Graves J, Furuno JP, Graffunder E, Lomaestro B, McGregor JC: Predictors of 30-day mortality among patients with Pseudomonas aeruginosa bloodstream infections: impact of delayed appropriate antibiotic selection. Antimicrob Agents Chemother. 2007, 51 (10): 3510-3515. 10.1128/AAC.00338-07.CrossRefPubMedPubMedCentral
37.
go back to reference El-Solh AA, Hattemer A, Hauser AR, Alhajhusain A, Vora H: Clinical outcomes of type III Pseudomonas aeruginosa bacteremia. Crit Care Med. 2012, 40 (4): 1157-1163. 10.1097/CCM.0b013e3182377906.CrossRefPubMedPubMedCentral El-Solh AA, Hattemer A, Hauser AR, Alhajhusain A, Vora H: Clinical outcomes of type III Pseudomonas aeruginosa bacteremia. Crit Care Med. 2012, 40 (4): 1157-1163. 10.1097/CCM.0b013e3182377906.CrossRefPubMedPubMedCentral
Metadata
Title
Effect of metallo-β-lactamase production and multidrug resistance on clinical outcomes in patients with Pseudomonas aeruginosabloodstream infection: a retrospective cohort study
Authors
Matthias Willmann
Ines Kuebart
Matthias Marschal
Klaus Schröppel
Wichard Vogel
Ingo Flesch
Uwe Markert
Ingo B Autenrieth
Florian Hölzl
Silke Peter
Publication date
01-12-2013
Publisher
BioMed Central
Published in
BMC Infectious Diseases / Issue 1/2013
Electronic ISSN: 1471-2334
DOI
https://doi.org/10.1186/1471-2334-13-515

Other articles of this Issue 1/2013

BMC Infectious Diseases 1/2013 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine